- Home
- CRBP
as 11-04-2025 4:00pm EST
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Upcoming Earnings Alert:
Get ready for potential market movements as Corbus Pharmaceuticals Holdings Inc. CRBP prepares to release earnings report on 07 Nov 2025.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NORWOOD |
| Market Cap: | 233.5M | IPO Year: | N/A |
| Target Price: | $49.00 | AVG Volume (30 days): | 561.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.64 - $20.77 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 220.00% |
Stock Insider Trading Activity of Corbus Pharmaceuticals Holdings Inc. (CRBP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Yuval | CRBP | Chief Executive Officer | Oct 27 '25 | Sell | $17.14 | 8,973 | $153,797.22 | 138,187 | |
| Moran Sean F. | CRBP | Chief Financial Officer | Oct 24 '25 | Sell | $17.02 | 12,981 | $220,936.62 | 73,313 | |
| Cohen Yuval | CRBP | Chief Executive Officer | Oct 24 '25 | Sell | $17.01 | 18,660 | $317,406.60 | 138,187 | |
| Altmeyer Anne | CRBP | Director | Oct 20 '25 | Sell | $20.50 | 1,060 | $21,730.00 | 6,191 |
Latest Corbus Pharmaceuticals Holdings Inc. News
CRBP Breaking Stock News: Dive into CRBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Corbus Pharmaceuticals Announces Pricing of Public Offering
GlobeNewswire
6 days ago
Corbus Pharmaceuticals Announces Proposed Public Offering
MT Newswires
16 days ago
Wedbush Raises Price Target on Corbus Pharmaceuticals Holdings to $38 From $31, Keeps Outperform Rating
GlobeNewswire
18 days ago
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
GlobeNewswire
22 days ago
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
GlobeNewswire
a month ago
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
MT Newswires
a month ago
Top Premarket Decliners
GlobeNewswire
4 months ago
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
Compare CRBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRBP Corbus Pharmaceuticals Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.